SAFER-Sample™ Kit

The SAFER-Sample™ Kit is a saliva sample collection kit intended for the storage, collection, preservation, and transport of viral ribonucleic acid (RNA) at room temperature for up to a week for subsequent molecular testing of RNA viruses such as SARS-CoV-2. The US Food and Drug Administration (FDA) has approved saliva[1] as a sample type for testing SARS-CoV-2. Saliva is regarded as a promising non-invasive specimen for diagnosis, monitoring, and infection control in patients with SARS-CoV-2 infection[2].

Conventional methods[3] state that virus specimens should be stored and shipped at 2°C to 8°C if they will reach the laboratory in < 72 hours, and at < -70°C on dry ice or liquid nitrogen if they will reach the laboratory in > 72 hours due to delay in testing or shipping. Samples not chilled immediately on collection may degrade rapidly, increasing risk of false-negative results.

Benefits

1. Less specimen degradation from delayed processing means fewer false-negative results from specimen degradation
2. No requirement for chilled transport media, hence reducing challenges of cold chain
3. Non-invasive saliva specimen self-collection without invasive collection methods
4. Self-collected saliva reduces healthcare personnel involvement and aerosols from swabbing, hence leading to greater safety and efficiency

AMPLICATION PLOT OF SAFER-Sample™ SUCCESSFULLY STABILIZING VIRAL RNA OVER 48 HOURS AT 37°C COMPARED TO OTHER METHOD



Figure 1. Company data on performance of SAFER-Sample™ compared to other RNA stabilizer

AMPLICATION PLOT OF SAFER-Sample™ SUCCESSFULLY STABILIZING VIRAL RNA OVER 24 HOURS AT 37°C COMPARED TO UTM



Figure 2. Company data on performance of SAFER-Sample™ compared to UTM

From Figure 1, no degradation was observed in the RT-PCR amplification plot with SAFER-Sample™ over 48 hours as compared to other commercial methods (left shifted graphs have higher signals on log-basis). Viral inactivation by SAFER-Sample™ is currently being evaluated.

About us

Lucence is a precision oncology company headquartered in Singapore and California. Its liquid biopsy clinical services are delivered worldwide through a US CLIA-licensed and CAP-accredited laboratory.

International Physicians (Outside Singapore): The SAFER-Sample™ Kit is developed, designed, and sold exclusively for research use only. It is not a test for any disease. Collection and processing of saliva samples for any purpose shall be conducted in accordance with local healthcare regulations. Lucence is not responsible for any injury, loss or damages arising from use outside intended use.

[1] https://www.rutgers.edu/news/new-rutgers-saliva-test-coronavirus-gets-fda-approval
[2] https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa149/5734265
[3] https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html